Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer.

Life (Basel) · 2026 · PMC13117735 · PMID 42073374

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

An exploratory biomarker analysis revealed a qualitative interaction between KRAS mutation status and treatment sequencing benefit, although this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.